Related Experiment Video

Updated: Jun 22, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with

F Marc LaForce1, Neil Ravenscroft, Mamoudou Djingarey

  • 1PATH, 13 Chemin du Levant, Ferney-Voltaire 01210, France. fmlaforce@path.org

Vaccine
|May 30, 2009
PubMed

Insights

A new meningococcal A conjugate vaccine (MenAfriVac) shows promise for ending African meningitis epidemics. This safe vaccine generates a strong immune response, potentially leading to herd immunity and preventing future outbreaks.

Area of Science:

  • Public Health
  • Vaccinology
  • Infectious Diseases

Background:

  • Epidemic meningitis caused by Group A Neisseria meningitidis is a persistent public health challenge in Africa.
  • Current control relies on reactive polysaccharide vaccination, which is logistically difficult and ineffective in preventing recurrent epidemics.
  • The meningococcal Group A capsule is a key virulence factor, driving epidemic meningitis during the dry season.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of a novel meningococcal A conjugate vaccine (MenAfriVac).
  • To assess the potential of MenAfriVac to control Group A meningococcal meningitis epidemics in Africa.

Main Methods:

  • Phase II clinical trials were conducted in Africa to test the meningococcal A conjugate vaccine (MenAfriVac).
  • Safety and immunologic responses, including functional antibody levels, were assessed.

Main Results:

  • The meningococcal A conjugate vaccine (MenAfriVac) demonstrated a favorable safety profile.
  • The vaccine induced a sustained immunologic response with functional antibody levels significantly higher (20-fold) than those from polysaccharide vaccines.
  • The immunogenicity suggests potential for generating herd immunity.

Conclusions:

  • MenAfriVac is a safe and immunogenic vaccine for preventing Group A meningococcal meningitis.
  • Widespread use of MenAfriVac could lead to herd immunity and eradicate Group A meningococcal epidemics in Africa.
  • This conjugate vaccine offers a proactive strategy to control a major public health problem.

More Related Videos

Neisseria meningitidis Infection of Induced Pluripotent Stem-Cell Derived Brain Endothelial Cells10:12

Neisseria meningitidis Infection of Induced Pluripotent Stem-Cell Derived Brain Endothelial Cells

Published on: July 14, 2020

Related Concept Videos

Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...